Zoetis Inc. (LON:0M3Q)

London flag London · Delayed Price · Currency is GBP · Price in USD
168.78
-0.72 (-0.42%)
At close: Jun 5, 2025
-1.48%
Market Cap 55.22B
Revenue (ttm) 7.19B
Net Income (ttm) 1.95B
Shares Out n/a
EPS (ttm) 4.31
PE Ratio 28.33
Forward PE 26.54
Dividend 1.45 (0.86%)
Ex-Dividend Date Apr 21, 2025
Volume 2,787
Average Volume 6,072
Open 168.41
Previous Close 169.50
Day's Range 168.18 - 169.86
52-Week Range 139.92 - 200.19
Beta 0.94
RSI 60.57
Earnings Date Aug 5, 2025

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1950
Employees 13,800
Stock Exchange London Stock Exchange
Ticker Symbol 0M3Q
Full Company Profile

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD Financial Statements

News

Zoetis Releases 2024 Sustainability Progress Update

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis published its 2024 Sustainability Progress Update “Advancing Sustainability in Animal Health for a Better Future” to highlight the comp...

1 day ago - Business Wire

How pet medicine stocks could cushion your healthcare investments from Trump changes

Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...

3 days ago - Yahoo Finance

Top 15 High-Growth Dividend Stocks For June 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, thoug...

4 days ago - Seeking Alpha

Dr. Mark Stetter Elected to Zoetis Board of Directors

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual share...

14 days ago - Business Wire

Zoetis Declares Third Quarter 2025 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will b...

15 days ago - Business Wire

Lightning Round: Mosaic is up too much, don't buy here, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stocks including: DeFi Technologies, ESCO Technologies, ZIM Integrated Shipping, Mosaic, and Zoetis.

16 days ago - CNBC

Zoe supplement ad banned over ultra-processed claims

The ASA said the ad for Daily30+ was likely to mislead consumers by implying that the product did not contain any ultra-processed ingredients.

16 days ago - Evening Standard

A Look Into Zoetis Inc's Price Over Earnings

In the current market session, Zoetis Inc. (NYSE: ZTS) share price is at $161.01, after a 1.25% decrease. Over the past month, the stock increased by 8.79% , but over the past year, it actually fell ...

18 days ago - Benzinga

Zoetis to Participate in Upcoming Investor Conferences

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. BNP Pari...

22 days ago - Business Wire

Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services

Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.

4 weeks ago - CNBC Television

Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services

Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.

4 weeks ago - CNBC

Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)

Zoetis shifts from sell to hold as solid earnings, strong balance sheet, and tailwinds like a weaker dollar suggest fair value and potential 8%+ returns.

4 weeks ago - Seeking Alpha

Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck

Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.

4 weeks ago - CNBC Television

Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck

Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.

4 weeks ago - CNBC

Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact

Animal health firm Zoetis Inc (NYSE: ZTS) on Tuesday reported a first-quarter 2025 adjusted EPS of $1.48, up from $1.38 a year ago, beating the consensus of $1.39 . Adjusted net income for the first ...

4 weeks ago - Benzinga

Zoetis raises forecast for 2025 revenue, profit on weaker US dollar

Animal healthcare company Zoetis on Tuesday raised its forecasts for annual adjusted profit and revenue above Wall Street expectations, after beating first-quarter estimates, benefiting from a weak U....

4 weeks ago - Reuters

Zoetis Announces First Quarter 2025 Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company...

4 weeks ago - Business Wire